BioSpace Editorial Staff
Odyssey Therapeutics Launched: December 2021 Location: Cambridge, MA Series A: $218M Series B: $168M
Notable: Odyssey is on a journey to discover and develop novel targets. The company has so far declared eight programs in immunology and oncology. Differentiator: Odyssey is rapidly expanding. Just ten months after securing $218 million in Series A funds, the company closed an oversubscribed Series B worth $168 million. As of October 2022, Odyssey counted more than 160 team members.
Leadership: Odyssey is helmed by serial biotech entrepreneur Gary Glick, Ph.D., who has founded several companies including IFM Therapeutics, Scorpion Therapeutics and First Wave Bio.